(CLX) The Clorox - Ratings and Ratios
Cleaning Products, Laundry Additives, Cat Litter, Food Products, Personal Care
CLX EPS (Earnings per Share)
CLX Revenue
Description: CLX The Clorox
The Clorox Company is a global consumer goods manufacturer with a diverse portfolio of brands across four business segments: Health and Wellness, Household, Lifestyle, and International. The companys product offerings range from home care and cleaning products to cat litter, grilling products, and natural personal care items, with a presence in multiple markets worldwide.
Key Performance Indicators (KPIs) that can be used to evaluate Cloroxs performance include revenue growth, gross margin, operating cash flow, and return on equity (ROE). With a ROE of 742.25, Clorox demonstrates a strong ability to generate profits from shareholder equity. Additionally, the companys diversified brand portfolio and global reach provide a solid foundation for long-term growth.
Cloroxs business segments offer a range of products that cater to different consumer needs, from essential household items to lifestyle products. The companys commitment to innovation and brand management is evident in its efforts to expand its e-commerce channels and digital presence. With a strong brand portfolio and global distribution network, Clorox is well-positioned to capitalize on emerging trends and consumer preferences.
From a valuation perspective, Cloroxs price-to-earnings (P/E) ratio of 22.74 and forward P/E of 17.83 suggest a relatively stable valuation compared to its earnings growth prospects. The companys market capitalization of $15.64 billion indicates a significant presence in the consumer goods sector. Overall, Cloroxs diversified business model, strong brand portfolio, and global reach make it an attractive investment opportunity for those seeking exposure to the consumer staples sector.
CLX Stock Overview
| Market Cap in USD | 14,630m |
| Sub-Industry | Household Products |
| IPO / Inception | 1983-03-21 |
CLX Stock Ratings
| Growth Rating | -45.3% |
| Fundamental | 74.4% |
| Dividend Rating | 60.6% |
| Return 12m vs S&P 500 | -33.0% |
| Analyst Rating | 3.05 of 5 |
CLX Dividends
| Dividend Yield 12m | 5.13% |
| Yield on Cost 5y | 3.37% |
| Annual Growth 5y | 2.76% |
| Payout Consistency | 86.7% |
| Payout Ratio | 63.7% |
CLX Growth Ratios
| Growth Correlation 3m | -45.2% |
| Growth Correlation 12m | -93.8% |
| Growth Correlation 5y | -40.5% |
| CAGR 5y | -0.96% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.03 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.07 |
| Sharpe Ratio 12m | -0.37 |
| Alpha | -34.43 |
| Beta | 0.515 |
| Volatility | 21.97% |
| Current Volume | 1224.1k |
| Average Volume 20d | 1612.8k |
| Stop Loss | 116.1 (-3%) |
| Signal | 0.31 |
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income (810.0m TTM) > 0 and > 6% of Revenue (6% = 426.2m TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA 5.29pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -4.38% (prev 0.68%; Δ -5.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.18 (>3.0%) and CFO 981.0m > Net Income 810.0m (YES >=105%, WARN >=100%) |
| Net Debt (2.71b) to EBITDA (1.45b) ratio: 1.87 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (123.7m) change vs 12m ago -1.05% (target <= -2.0% for YES) |
| Gross Margin 45.23% (prev 42.90%; Δ 2.33pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 125.6% (prev 123.3%; Δ 2.27pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 12.67 (EBITDA TTM 1.45b / Interest Expense TTM 88.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.30
| (A) -0.06 = (Total Current Assets 1.61b - Total Current Liabilities 1.92b) / Total Assets 5.56b |
| (B) 0.08 = Retained Earnings (Balance) 432.0m / Total Assets 5.56b |
| (C) 0.20 = EBIT TTM 1.11b / Avg Total Assets 5.66b |
| (D) 0.08 = Book Value of Equity 406.0m / Total Liabilities 5.08b |
| Total Rating: 1.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 74.37
| 1. Piotroski 8.50pt = 3.50 |
| 2. FCF Yield 4.39% = 2.19 |
| 3. FCF Margin 10.71% = 2.68 |
| 4. Debt/Equity 8.97 = -2.50 |
| 5. Debt/Ebitda 1.87 = 0.26 |
| 6. ROIC - WACC (= 27.93)% = 12.50 |
| 7. RoE 882.8% = 2.50 |
| 8. Rev. Trend 6.00% = 0.45 |
| 9. EPS Trend 55.74% = 2.79 |
What is the price of CLX shares?
Over the past week, the price has changed by -0.54%, over one month by -1.59%, over three months by -4.45% and over the past year by -22.76%.
Is The Clorox a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLX is around 109.88 USD . This means that CLX is currently overvalued and has a potential downside of -8.22%.
Is CLX a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 13
- Sell: 3
- Strong Sell: 1
What are the forecasts/targets for the CLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 130.8 | 9.2% |
| Analysts Target Price | 130.8 | 9.2% |
| ValueRay Target Price | 120.6 | 0.7% |
Last update: 2025-10-13 02:03
CLX Fundamental Data Overview
P/E Trailing = 18.4264
P/E Forward = 19.6464
P/S = 2.0594
P/B = 46.5805
P/EG = 3.4454
Beta = 0.515
Revenue TTM = 7.10b USD
EBIT TTM = 1.11b USD
EBITDA TTM = 1.45b USD
Long Term Debt = 2.48b USD (from longTermDebt, last quarter)
Short Term Debt = 91.0m USD (from shortTermDebt, last quarter)
Debt = 2.88b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.71b USD (from netDebt column, last quarter)
Enterprise Value = 17.34b USD (14.63b + Debt 2.88b - CCE 167.0m)
Interest Coverage Ratio = 12.67 (Ebit TTM 1.11b / Interest Expense TTM 88.0m)
FCF Yield = 4.39% (FCF TTM 761.0m / Enterprise Value 17.34b)
FCF Margin = 10.71% (FCF TTM 761.0m / Revenue TTM 7.10b)
Net Margin = 11.40% (Net Income TTM 810.0m / Revenue TTM 7.10b)
Gross Margin = 45.23% ((Revenue TTM 7.10b - Cost of Revenue TTM 3.89b) / Revenue TTM)
Gross Margin QoQ = 46.48% (prev 44.60%)
Tobins Q-Ratio = 3.12 (Enterprise Value 17.34b / Total Assets 5.56b)
Interest Expense / Debt = 0.76% (Interest Expense 22.0m / Debt 2.88b)
Taxrate = 18.05% (74.0m / 410.0m)
NOPAT = 913.8m (EBIT 1.11b * (1 - 18.05%))
Current Ratio = 0.84 (Total Current Assets 1.61b / Total Current Liabilities 1.92b)
Debt / Equity = 8.97 (Debt 2.88b / totalStockholderEquity, last quarter 321.0m)
Debt / EBITDA = 1.87 (Net Debt 2.71b / EBITDA 1.45b)
Debt / FCF = 3.57 (Net Debt 2.71b / FCF TTM 761.0m)
Total Stockholder Equity = 91.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.57% (Net Income 810.0m / Total Assets 5.56b)
RoE = 882.8% (Net Income TTM 810.0m / Total Stockholder Equity 91.8m)
RoCE = 43.29% (EBIT 1.11b / Capital Employed (Equity 91.8m + L.T.Debt 2.48b))
RoIC = 34.64% (NOPAT 913.8m / Invested Capital 2.64b)
WACC = 6.71% (E(14.63b)/V(17.51b) * Re(7.91%) + D(2.88b)/V(17.51b) * Rd(0.76%) * (1-Tc(0.18)))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.35%
[DCF Debug] Terminal Value 79.79% ; FCFE base≈649.8m ; Y1≈724.3m ; Y5≈954.5m
Fair Price DCF = 136.1 (DCF Value 16.57b / Shares Outstanding 121.8m; 5y FCF grow 13.23% → 3.0% )
EPS Correlation: 55.74 | EPS CAGR: 50.65% | SUE: 1.92 | # QB: 1
Revenue Correlation: 6.00 | Revenue CAGR: 4.96% | SUE: 0.61 | # QB: 0
Additional Sources for CLX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle